Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/coagulation-analyzer-technology-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Coagulation Analyzer TechnologyCoagulation analyzer patents: who leads and where filing is heading
- Concentrated at the top. The five leading assignees hold 27.6% of all 1,824 records in scope, and the leading ten hold 45.3% — a field where a handful of filers occupy nearly half the claim space.
- Filing has cooled from its 2018 peak. Annual filings ran from 104 in 2017 to a peak of 126 in 2018, then declined 43% between 2021 (81) and 2024 (46), the most recent year with a complete publication picture.
- Chemistry classes outweigh instrumentation classes. A61K medicinal-preparation claims touch 60.9% of records versus 24.0% for G01N material-analysis claims, meaning much of this corpus is reagent and compound work adjacent to the analyzer hardware itself.
1,824
Published Records
28%
Top-5 Share of All Records
-43%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (81 records) with 2024 (46) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,824 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Coagulation analyzer technology sits at the intersection of instrument design and reagent chemistry: mechanical and optical clot detection, cuvette and reagent-handling hardware, and the compounds that drive or modulate the clotting reaction being measured. This dataset spans 1,824 published patent families filed or published between 2015 and mid-2026, pulled from records that reference coagulation or hemostasis analyzers alongside mechanical clot detection, optical turbidity, reagent temperature control, cuvette design, instrument throughput, or maintenance.
Because the search terms bridge instrument claims and pharmaceutical claims, the corpus mixes analyzer hardware assignees with drug developers whose compounds are tested using these instruments. That mix explains why medicinal-preparation and therapeutic-activity IPC classes outnumber the material-analysis class most readers would expect to dominate a coagulation analyzer search.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trends and technology composition
Annual filing counts and IPC subclass shares for the 1,824 records in scope, drawn directly from the underlying dataset.
Filing trend, 2017-2026
Filings rose from 104 in 2017 to a peak of 126 in 2018, then eased through the early 2020s; the 2021-to-2024 span shows a 43% decline (81 to 46). 2025 and 2026 figures are still filling in as publication typically lags filing by around 18 months, so the apparent tail-off in the most recent two years should not be read as the current filing rate.
IPC subclass composition
A61K (medicinal preparations) appears on 60.9% of records, ahead of A61P (25.8%), G01N (24.0%), C07K (23.9%) and C12N (16.4%); A61M, A61L and C12Q each sit below 8%. Records can carry multiple classes, so these shares sum to well over 100% and are not mutually exclusive segments of the field.
Shares are the percentage of the 1,824 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Coagulation Analyzer Technology with Eureka
This page is one run against one query. Ask Eureka your own question about coagulation analyzer technology and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Most-cited records in this landscape
Representative Filing
Blood coagulation analyzer, blood coagulation analysis method, and computer program product (US20110014640A1, Sysmex)
SYSMEX CORPORATION
The filing describes an analyzer that minimizes dedicated fibrinogen (Fbg) reagent use by deriving a fibrinogen concentration from data already produced during a routine PT measurement. It detects transmitted light intensity from a sample prepared with blood and PT reagent, derives a dFbg value from that signal, and determines whether the value falls within a set range before deciding how to proceed with fibrinogen reporting.Abstract text is drawn directly from the published filing.
Highest-citation records
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1999037304A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | 320 |
| 2 | US6524861B1 | Blood coagulation analyzer | 268 |
| 3 | US5646046A | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis | 213 |
| 4 | WO2001007436A2 | Substituted oxoazaheterocyclyl compounds | 198 |
| 5 | US20030064414A1 | Rapid assessment of coagulation activity in whole blood | 180 |
| 6 | WO2009137254A2 | Modified factor ix polypeptides and uses thereof | 177 |
| 7 | WO2011060242A2 | Von willebrand factor (VWF)-containing preparations, and methods, kits, and uses related thereto | 150 |
| 8 | US20120201756A1 | Plasma kallikrein binding proteins | 142 |
| 9 | CA2675836A1 | Composition for preventing or treating thrombus- or embolus-associated disease | 125 |
| 10 | WO2009140015A2 | Site-directed modification of factor ix | 122 |
Citation counts accumulate over time within the searched corpus, so older records are structurally favoured; treat this table as a signal of historical influence rather than current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers indicate
Four patterns stand out once filing volume, assignee concentration and technology composition are read together.
Concentration
27.6% / 45.3%
share of 1,824 records held by top 5 / top 10 assignees
Claim space is held by a narrow group
The five leading assignees account for 27.6% of all records in scope, and the leading ten for 45.3%. For a new entrant, this means the highest-value hardware and reagent-interaction claims near the analyzer core are likely already staked out by a small set of filers.
Based on the full 100-company ranking
Momentum
-43%
filings, 2021 (81) to 2024 (46)
Filing activity has cooled from its 2018 peak
After peaking at 126 filings in 2018, annual volume declined to 46 by 2024, the last year with a complete publication record. That is a genuine slowdown in the completed data, not an artifact of publication lag, since 2024 has had time to fully populate.
2025-2026 figures still filling in due to publication lag
Composition
60.9%
of 1,824 records carry an A61K class
Chemistry claims outnumber instrumentation claims
A61K medicinal-preparation claims touch 60.9% of records, more than double the 24.0% carrying G01N material-analysis claims. Anyone scoping purely mechanical or optical clot-detection prior art needs to filter out a large volume of reagent-and-compound filings that share the same search terms.
Records may carry multiple IPC classes
Geography
461
US-filed records, the largest single receiving office
US and EPO dominate filing venue
The United States leads with 461 records, ahead of EPO at 291 and WIPO/PCT at 175; Australia, Israel and Canada each sit in the 90-125 range. Filing strategy in this field still runs primarily through the largest single markets rather than broad PCT-first coverage.
Receiving office counts, not family counts
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to coagulation analyzer technology, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where momentum is shifting
The ranked leaders span analyzer hardware makers and pharmaceutical companies whose compounds are tested on these instruments, reflecting the mixed nature of the underlying search terms.
Leader
125
records from the top-ranked assignee
A single filer sits well ahead of the field
The leading assignee holds 125 records, meaningfully ahead of the fifth-place filer at 77 and the tenth-place filer at 62. The gap between first and fifth place is wider than the gap between fifth and tenth, indicating one dominant filer atop a more evenly spread group.
Full ranking covers 100 companies
Momentum
-75% to -100%
YoY change among several named filers
Recent-year activity has dropped across established filers
Several previously active assignees show sharp declines or zero filings in the latest year, including drops of -75% and -96% year-over-year and multiple filers at -100%. This pattern is consistent with the broader 2021-2024 filing decline rather than isolated to any one company.
Latest-year counts are still subject to publication lag
Collaboration
10
co-assignee pairs identified
Co-filing is limited but concentrated where it exists
Only ten co-assignee pairs appear in the dataset, with the strongest pairing linking two organisations across 38 shared records. Where collaboration exists, it tends to be a small number of deep, repeated pairings rather than broad cross-industry co-filing.
Pair counts reflect shared record filings
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals Inc | 2 | -75% |
| Hitachi High-Tech Corporation | 2 | — |
| Velico Medical Inc | 1 | -96% |
| Bioverativ Therapeutics Inc | 0 | -100% |
| Sysmex Corporation | 0 | -100% |
| Bayer HealthCare LLC | 0 | — |
| Pfizer Inc | 0 | — |
| Cerus Corporation | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or R&D scoping.
Scope freedom-to-operate around the top filers
With 45.3% of records held by ten assignees, an FTO review should start by mapping their claim scope in mechanical and optical clot detection before assessing the long tail.
Explore assignee claims in EurekaTest the white-space branches for a first filing
Reagent temperature stabilization, cuvette geometry and instrument throughput scheduling show comparatively thin dedicated coverage relative to the chemistry-heavy core of this corpus.
Run a white-space search in EurekaWatch for renewed filing once the lag clears
2024's 46 filings mark a real decline from 2018's peak, but 2025-2026 figures are still incomplete; re-check momentum once publication catches up.
Track filing trends in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on coagulation analyzer patents
The ranking covers 100 companies, with the top filer holding 125 records against 77 for the fifth-placed assignee and 62 for the tenth. The leading five assignees together account for 27.6% of the 1,824 records in scope, and the leading ten for 45.3%, so a meaningful share of filings sit outside this group across a long tail of single- and few-filing entrants. The mix includes both dedicated analyzer/hardware makers and pharmaceutical companies whose compounds are validated using coagulation testing instruments.
Filings peaked at 126 in 2018 after starting at 104 in 2017, then declined to 46 by 2024, a drop of 43% from the 81 filed in 2021. 2024 is the most recent year with a complete publication picture, so this decline reflects genuine cooling rather than a data artifact. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so no conclusion should be drawn yet about the very latest filing rate.
A61K, covering medicinal preparations, appears on 60.9% of the 1,824 records, making it the single most common IPC subclass in this corpus. G01N, the material-analysis and testing class most directly tied to analyzer hardware, covers 24.0% of records, with A61P (25.8%) and C07K (23.9%) also prominent. Because the search terms span both instrument claims and compound claims, and a single record can carry several IPC classes, chemistry-related classes outnumber pure instrumentation classes in this dataset.
Instrumentation-specific sub-areas such as reagent temperature stabilization, cuvette geometry for low-volume samples, automated maintenance and self-diagnostic routines, and instrument throughput scheduling logic sit outside the densest chemistry-heavy IPC clusters in this corpus. These branches receive comparatively limited dedicated claim coverage relative to A61K and A61P filings, which suggests room for narrowly scoped hardware or workflow claims rather than broad compound claims. Any white-space assessment should still be checked against the full assignee ranking before filing, since claim density can vary sharply within a subclass.
US20110014640A1, assigned to Sysmex, describes a blood coagulation analyzer that derives a fibrinogen concentration from data collected during a routine PT measurement rather than requiring a dedicated fibrinogen reagent test. It detects transmitted light intensity from a blood-and-PT-reagent sample, computes a dFbg value from that signal, and checks whether the value falls within a predetermined range before determining how to report fibrinogen results. The filing is representative of a broader pattern in this dataset where instrument workflow claims reduce reagent consumption while reusing existing optical measurement steps.
Answers are grounded in the same dataset. Derived from a Patsnap search on Coagulation Analyzer Technology covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Coagulation Analyzer Technology in depth with Eureka
Go past this page: query the whole coagulation analyzer technology corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.